齐齐哈尔医学院学报
齊齊哈爾醫學院學報
제제합이의학원학보
JOURNAL OF QIQIHAR MEDICAL COLLEGE
2015年
16期
2357-2359
,共3页
精神分裂症%阴性症状%氨磺必利%无抽搐电休克治疗
精神分裂癥%陰性癥狀%氨磺必利%無抽搐電休剋治療
정신분렬증%음성증상%안광필리%무추휵전휴극치료
Schizophrenia%Negative Symptoms%Amisulpride%Modified electroconvulsive treatment
目的:探讨无抽搐电休克( MECT)联合氨磺必利与单用氨磺必利治疗精神分裂症阴性症状的疗效及安全性。方法将80例阴性症状为主的精神分裂症患者分为无抽搐电休克联合氨磺必利治疗组(联合组)和单用氨磺必利治疗组(单用组),每组均40例,疗程为8周,采用阳性与阴性症状量表( Positive and Negative Syndrome Scale ,PANSS)评定疗效,韦氏记忆量表( Wechsler Memory Scale ,WMS)评定记忆状况以及不良反应量表(Treatment Emergent Symptom Scale ,TESS)评定不良反应。结果第8周末,联合组治疗有效率显著高于单用组有效率(87.5% vs 67.5%,P<0.05);联合组PANSS总分及阴性因子评分(分别为46.7±14.2,18.4±6.0)低于单用组(分别为55.2±13.9,22.9±6.4),差异具有统计学意义(t=2.66、3.69,P均<0.01),TESS评分无统计学差异;第8周末联合组韦氏记忆量表的图片、再认、背数记忆及联想4个因子与本组治疗前相比无明显差异(P>0.05)。结论无抽搐电休克联合氨磺必利治疗精神分裂症的阴性症状疗效显著,优于单用氨磺必利治疗,起效快,安全可靠,对记忆影响是短暂而可逆的。
目的:探討無抽搐電休剋( MECT)聯閤氨磺必利與單用氨磺必利治療精神分裂癥陰性癥狀的療效及安全性。方法將80例陰性癥狀為主的精神分裂癥患者分為無抽搐電休剋聯閤氨磺必利治療組(聯閤組)和單用氨磺必利治療組(單用組),每組均40例,療程為8週,採用暘性與陰性癥狀量錶( Positive and Negative Syndrome Scale ,PANSS)評定療效,韋氏記憶量錶( Wechsler Memory Scale ,WMS)評定記憶狀況以及不良反應量錶(Treatment Emergent Symptom Scale ,TESS)評定不良反應。結果第8週末,聯閤組治療有效率顯著高于單用組有效率(87.5% vs 67.5%,P<0.05);聯閤組PANSS總分及陰性因子評分(分彆為46.7±14.2,18.4±6.0)低于單用組(分彆為55.2±13.9,22.9±6.4),差異具有統計學意義(t=2.66、3.69,P均<0.01),TESS評分無統計學差異;第8週末聯閤組韋氏記憶量錶的圖片、再認、揹數記憶及聯想4箇因子與本組治療前相比無明顯差異(P>0.05)。結論無抽搐電休剋聯閤氨磺必利治療精神分裂癥的陰性癥狀療效顯著,優于單用氨磺必利治療,起效快,安全可靠,對記憶影響是短暫而可逆的。
목적:탐토무추휵전휴극( MECT)연합안광필리여단용안광필리치료정신분렬증음성증상적료효급안전성。방법장80례음성증상위주적정신분렬증환자분위무추휵전휴극연합안광필리치료조(연합조)화단용안광필리치료조(단용조),매조균40례,료정위8주,채용양성여음성증상량표( Positive and Negative Syndrome Scale ,PANSS)평정료효,위씨기억량표( Wechsler Memory Scale ,WMS)평정기억상황이급불량반응량표(Treatment Emergent Symptom Scale ,TESS)평정불량반응。결과제8주말,연합조치료유효솔현저고우단용조유효솔(87.5% vs 67.5%,P<0.05);연합조PANSS총분급음성인자평분(분별위46.7±14.2,18.4±6.0)저우단용조(분별위55.2±13.9,22.9±6.4),차이구유통계학의의(t=2.66、3.69,P균<0.01),TESS평분무통계학차이;제8주말연합조위씨기억량표적도편、재인、배수기억급련상4개인자여본조치료전상비무명현차이(P>0.05)。결론무추휵전휴극연합안광필리치료정신분렬증적음성증상료효현저,우우단용안광필리치료,기효쾌,안전가고,대기억영향시단잠이가역적。
Objective To investigate the efficacy and safety of amisulpride combined with MECT and amisulpride respectively in the treatment of negative symptoms of schizophrenia patients .Methods 80 schizophrenia patients with predominant negative symptoms were divided into the combined group ( amisulpride combined with MECT) and the control group (amisulpride only), each group had 40 patients.The efficacy was assessed by PANSS ( Positive and Negative Syndrome Scale ) , memory states and side effects were assessed by WMS ( Wechsler Memory Scale ) and TESS ( Treatment Emergent Symptom Scale ) .Results After 8-week treatment, the response rate of the combined group was higher than the control group (87.5% vs.67.5%,P<0.05), the combined patients scored less in PANSS score and negative factor score than the control group (separately 46.7 ±14.2 vs.55.2 ±13.9, 18.4 ±6.0 vs.22.9 ±6.4, t=2.66、3.69, all P<0.01), no significant difference were found in TESS score between the two groups .In the combined group , no statistical difference were found in picture factor , recognition factor , number memory factor and association factor of WMS (all P>0.05) between before-and after-8-week treatment.Conclusions The efficacy of MECT combined with amisulpride is better than the single use of amisulpride in the treatment of negative symptoms of schizophrenia .